




CLL

MCL

WM

IMBRUVICA has broad experience over 3 B-cell malignancies¹⁻¹²



Values presented are median follow-up to the nearest round number.

* ALLIANCE: a randomised, open-label, cross-over assigned, phase III study comparing bendamustine plus rituximab with IMBRUVICA monotherapy in older (≥65 years), treatment-naïve patients (n=547) with CLL (median follow-up of 38 months). Patients that had a presence of del(11q) and/or del(17p)/TP53 mutations were not excluded from the study. Refer to the IMBRUVICA Summary of Product Characteristics for all licensed indications.^{6,12}

† Estimated median duration of follow-up across the three studies in the post-hoc pooled analysis.⁹

CLL=chronic lymphocytic leukaemia; MCL=mantle cell lymphoma; PH=phase; PT=pivotal trial; RR=relapsed/refractory; TN=treatment-naïve; WM=Waldenström's macroglobulinaemia.

